In March 2017 we wrote this article, "Breast Implants Linked to Rare Lymphoma Blood Cancer", which started our coverage of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) related to textured breast implants. Seven years later, we point out an article published on February 27, 2024, by the Plastic and Reconstructive Surgery … [Read more...]
Breast Implant-Associated Lymphoma: PROFILE Registry; Update on Number of Cases
From this recent FDA Safety Communication "UPDATE: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants" we get the following information about the new reporting system for cases of breast implant-associated lymphoma -- the shorthand term for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): As of March … [Read more...]
Health Canada Breast Implant Safety Review Shows High Risk of BIA-ALCL with Textured Implants
A recent Health Canada safety advisory comes following an updated safety review of breast implants and the associated risk of BIA-ALCL. According to the April 6, 2022 Health Canada advisory "Advisory - Updated safety review of breast implants underscores the continuing importance of monitoring for cancer; increased risk with highly textured … [Read more...]
FDA Sets New Regulations for Breast Implant Manufacturers
An October 2021 article, "FDA sets stronger safety warnings for breast implants", addresses the Food and Drug Administration's (FDA) new requirements for breast implant manufacturers. The new regulations will require patients receive detailed information about the potential risks and complications of implants prior to receiving surgery. However, … [Read more...]
BIA-ALCL Current Recommendations and Potential Future FDA Guidance Changes
History of BIA-ALCL In 2011, the Food and Drug Administration (FDA) reported 34 cases worldwide of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), bringing this unique disease into the public eye for the first time. Since then, BIA-ALCL has been recognized internationally as a distinct type of cancer, and prompted the 2019 … [Read more...]
BIA-ALCL Case Studies Confirm Importance of Proper Treatment
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare cancer of the immune system. BIA-ALCL has been closely linked with textured surface breast implants. What Causes BIA-ALCL? While BIA-ALCL is rare, it is very serious and potentially fatal if not treated properly. According to this December 2020 article, "Etiology of … [Read more...]
Black Box Warning Label Change for Breast Implants Finalized by the FDA
Since our previous article, “New BIA-ALCL Cases Identified in Updated FDA Report“, the FDA has finalized labeling guidance for breast implant manufacturers. The FDA label change is now requiring a black box label warning for the breast implant devices. In recent years, many textured breast implants have been linked to BIA-ALCL (breast … [Read more...]
New BIA-ALCL Cases Identified in Updated FDA Report
Since our previous article, "Most American Women Are Unaware of BIA-ALCL", the FDA has released an update on reports of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The update includes new BIA-ALCL case reports through January 5, 2020. What's New in BIA-ALCL Cases? Currently, the FDA analysis of global medical device … [Read more...]
Most American Women Are Unaware of BIA-ALCL
Since our previous article, Allergan Aesthetics Launches Tracking Campaign for U.S. Breast Implant Patients, recent news articles report the majority of American women are unaware of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Studies on BIA-ALCL Knowledge According to a July 2020 Practice Update article, 500 … [Read more...]
Allergan Aesthetics Launches Tracking Campaign for U.S. Breast Implant Patients
Since the July 2019 voluntary recall of textured breast implant Biocell, pharmaceutical company Allergan has been under fire. The recall came after research linked the implant with cases of breast implant associated anaplastic large cell lymphoma (BIA-ALCL). Allergan plans to launch a tracking campaign for U.S. breast implant patients in the near … [Read more...]